MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

19.02

-0.34 (-1.76%)

Jul 24, 2026, 4:00 PM EDT - Market closed

MLTX Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-259.47	-230.32	-121.24	-44.08	-64.51	-4.54
Depreciation & Amortization	3.08	2.62	1.39	0.37	0.16	-
Stock-Based Compensation	23.96	12.9	7.28	7.11	9.65	-
Other Adjustments	-0.77	-1.08	-0.23	0.04	0.37	-0.03
Change in Receivables	-2.77	-2.03	-1.79	-0.84	-0.07	-
Changes in Accounts Payable	11.37	20.56	7.16	1.58	-1.31	-
Changes in Accrued Expenses	11.27	2.59	5.17	-0.33	2.69	3.8
Changes in Other Operating Activities	-10.84	-1.25	-14.23	-6.63	-2.88	0.16
Operating Cash Flow	-224.15	-196.01	-116.59	-42.78	-55.89	-0.61
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-	-0.04	-0.52	-0.28	-0.02	-
Purchases of Investments	-235.89	-265.37	-350.28	-175.73	-42.23	-
Proceeds from Sale of Investments	382.74	468.4	145.2	150.83	9.9	-
Investing Cash Flow	146.84	202.99	-205.6	-25.18	-32.34	-

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Long-Term Debt Issued	24.47	73.02	-	-	-	-
Net Long-Term Debt Issued (Repaid)	24.47	73.02	-	-	-	-
Issuance of Common Stock	0.17	72.98	52.78	482.45	134.65	-
Net Common Stock Issued (Repurchased)	0.17	72.98	52.78	482.45	134.65	-
Other Financing Activities	-	-	-1.47	-2.75	-14.96	-0.06
Financing Cash Flow	103.52	146	51.31	479.7	119.69	-0.06

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	0.71	1.11	0.13	-0.08	0.01	-
Net Cash Flow	26.92	154.09	-270.74	411.66	31.47	-0.67

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-224.15	-196.04	-117.11	-43.06	-55.91	-0.61
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-3.37	-3.04	-1.86	-0.88	-1.47	-0.06
Levered Free Cash Flow	-220.12	-129.81	-119.97	-41.3	-65.87	-0.58
Unlevered Free Cash Flow	-253.61	-221	-144.46	-59.53	-66.46	3.96

SEC Filings: 10-K · 10-Q